Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941379 · ClinicalTrials.gov registry record
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
A clinical trial of Choroidal Melanoma and Indeterminate Lesions of Eye, sponsored by Aura Biosciences.
- Recruiting
- Registry status
- 500
- Enrollment target
- 16
- Study locations
NCT03941379 is a study of Choroidal Melanoma and Indeterminate Lesions of Eye that is actively recruiting participants, run by Aura Biosciences. The registered enrollment target is 500 participants, above the 50-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (900% higher). The trial reports 16 study locations across 12 states.
The verdict
NCT03941379, a study of Choroidal Melanoma and Indeterminate Lesions of Eye, is actively recruiting participants, sponsored by Aura Biosciences.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.
Conditions Studied
Study Locations (16)
California
- UCLA Jules Stein Eye Institute - Los Angeles
- Byers Eye Institute at Stanford University - Palo Alto
- Retina Consultants of Sacramento - Sacramento
Michigan
- W. K. Kellogg Eye Center, University of Michigan - Ann Arbor
- Associated Retinal Consultants, PC - Royal Oak
Texas
- Texas Retina Associates - Dallas
- Retina Consultants of Houston - Houston
Arizona
- Retina Associates SW, P.C. - Tucson
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Minnesota
- Retina Center - Minneapolis
New York
- Columbia University Medical Center - New York
Oregon
- Oregon Health & Science University Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2029-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941379
The ClinicalTrials.gov registry entry for NCT03941379 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (900% higher). The listed sponsor is Aura Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Choroidal Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT03941379 reports 16 study locations spanning 12 distinct geographic areas - top geographies include California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT03941379 about?
NCT03941379 is a clinical study titled "A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma". The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and ef...
What is the current status of trial NCT03941379?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-03-27. Estimated completion is 2029-12.
What conditions does trial NCT03941379 study?
This clinical trial studies the following conditions: Choroidal Melanoma, Indeterminate Lesions of Eye.
Who is sponsoring clinical trial NCT03941379?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03941379 being conducted?
This trial has 16 study locations across Arizona, California, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
COMPLETED · Phase 2
-
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.